ArticleMedicine2026
Preoperative gastric cancer immune prognostic score (GCIPS) as a novel biomarker for predicting survival in gastric cancer patients after radical resection: A retrospective cohort study.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to validate the preoperative gastric cancer immune prognostic score (GCIPS) as a prognostic biomarker in resectable gastric cancer (GC). We retrospectively analyzed 226 GC patients undergoing radical resection. The optimal cutoff value of the GCIPS was determined by receiver operating characteristic curve analysis, and patients were stratified accordingly to assess its prognostic value for recurrence-free survival and overall survival. The GCIPS was calculated using preoperative blood parameters. Using receiver operating characteristic-derived cutoff (2.840), patients were stratified into high- and low-GCIPS groups. The high-GCIPS group showed significantly poorer tumor differentiation (P < .001). Kaplan-Meier analysis revealed that high GCIPS was associated with worse 5-year recurrence-free survival (hazard ratio = 2.856, P < .001) and overall survival (hazard ratio = 3.222, P < .001). Multivariate analysis confirmed GCIPS as an independent predictor for both outcomes after adjusting for tumor-node-metastasis stage and differentiation. The GCIPS is a robust, independent prognostic biomarker derived from routine blood tests, offering a practical tool for risk stratification and guiding individualized management in GC after radical resection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.